273

The pharmaceutical lobby strongly opposed the Biden administration's plan to directly negotiate drug prices for 10 medications with Medicare. PhRMA argued this will hurt innovation, but advocates note that drug companies make 76% more than needed for R&D. Eliquis, which costs Medicare over $16 billion, will be subject to negotiations. The policy was enabled by the Inflation Reduction Act, which PhRMA spent millions lobbying against. PhRMA sued over the negotiations, but the DOJ moved to dismiss the case. Advocates believe this defeat of Big Pharma will not be the last as negotiations may expand to over 100 drugs in the future, greatly helping seniors and people with disabilities access affordable medications.

you are viewing a single comment's thread
view the rest of the comments
[-] taylus@lemmy.ml 22 points 1 year ago

tHiS wIlL hUrT iNnOvAtIoN

so tired of seeing this fucking response from parasite CEOs and their wannabe bootlickers

[-] deo@beehaw.org 14 points 1 year ago

Maybe if they didn't spend so much money on those horrible TV ads they'd have enough for R&D. And evergreening isn't innovation anyways, so idk what they're on about.

this post was submitted on 30 Aug 2023
273 points (100.0% liked)

Politics

10179 readers
101 users here now

In-depth political discussion from around the world; if it's a political happening, you can post it here.


Guidelines for submissions:

These guidelines will be enforced on a know-it-when-I-see-it basis.


Subcommunities on Beehaw:


This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.

founded 2 years ago
MODERATORS